Published in:
Open Access
01-12-2014 | Research article
High serum levels of Dickkopf-1 are associated with a poor prognosis in prostate cancer patients
Authors:
Tilman D Rachner, Stefanie Thiele, Andy Göbel, Andrew Browne, Susanne Fuessel, Kati Erdmann, Manfred P Wirth, Michael Fröhner, Tilman Todenhöfer, Michael H Muders, Matthias Kieslinger, Martina Rauner, Lorenz C Hofbauer
Published in:
BMC Cancer
|
Issue 1/2014
Login to get access
Abstract
Background
The Wnt inhibitor Dickkopf-1 (DKK-1) has been linked to the progression of malignant bone disease by impairing osteoblast activity. In addition, there is increasing data to suggest direct tumor promoting effects of DKK-1. The prognostic role of DKK-1 expression in prostate cancer remains unclear.
Methods
A prostate cancer tissue microarray (n = 400) was stained for DKK-1 and DKK-1 serum levels were measured in 80 patients with prostate cancer. The independent prognostic value of DKK-1 expression was assessed using multivariate analyses.
Results
DKK-1 tissue expression was significantly increased in prostate cancer compared to benign disease, but was not correlated with survival. However, high DKK-1 serum levels at the time of the diagnosis were associated with a significantly shorter overall and disease-specific survival. Multivariate analyses defined high serum levels of DKK-1 as an independent prognostic marker in prostate cancer (HR 3.73; 95%CI 1.44-9.66, p = 0.007).
Conclusion
High DKK-1 serum levels are associated with a poor survival in patients with prostate cancer. In light of current clinical trials evaluating the efficacy of anti-DKK-1 antibody therapies in multiple myeloma and solid malignancies, the measurement of DKK-1 in prostate cancer may gain clinical relevance.